Your browser doesn't support javascript.
loading
Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response.
Zhang, Ping; Kitchen-Smith, Isaac; Xiong, Lingyun; Stracquadanio, Giovanni; Brown, Katherine; Richter, Philipp H; Wallace, Marsha D; Bond, Elisabeth; Sahgal, Natasha; Moore, Samantha; Nornes, Svanhild; De Val, Sarah; Surakhy, Mirvat; Sims, David; Wang, Xuting; Bell, Douglas A; Zeron-Medina, Jorge; Jiang, Yanyan; Ryan, Anderson J; Selfe, Joanna L; Shipley, Janet; Kar, Siddhartha; Pharoah, Paul D; Loveday, Chey; Jansen, Rick; Grochola, Lukasz F; Palles, Claire; Protheroe, Andrew; Millar, Val; Ebner, Daniel V; Pagadala, Meghana; Blagden, Sarah P; Maughan, Timothy S; Domingo, Enric; Tomlinson, Ian; Turnbull, Clare; Carter, Hannah; Bond, Gareth L.
Affiliation
  • Zhang P; Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
  • Kitchen-Smith I; Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
  • Xiong L; Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
  • Stracquadanio G; Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
  • Brown K; Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
  • Richter PH; Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
  • Wallace MD; Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
  • Bond E; Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
  • Sahgal N; Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
  • Moore S; Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
  • Nornes S; Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
  • De Val S; Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
  • Surakhy M; Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
  • Sims D; Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, United Kingdom.
  • Wang X; Environmental Epigenomics and Disease Group, Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences-National Institutes of Health, Research Triangle Park, North Carolina.
  • Bell DA; Environmental Epigenomics and Disease Group, Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences-National Institutes of Health, Research Triangle Park, North Carolina.
  • Zeron-Medina J; Ludwig Institute for Cancer Research, University of Oxford, Nuffield Department of Clinical Medicine, Old Road Campus Research Building, Oxford, United Kingdom.
  • Jiang Y; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.
  • Ryan AJ; CRUK & MRC Oxford Institute for Radiation Oncology, University of Oxford, Department of Oncology, Old Road Campus Research Building, Oxford, United Kingdom.
  • Selfe JL; CRUK & MRC Oxford Institute for Radiation Oncology, University of Oxford, Department of Oncology, Old Road Campus Research Building, Oxford, United Kingdom.
  • Shipley J; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.
  • Kar S; Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom.
  • Pharoah PD; Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • Loveday C; Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • Jansen R; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.
  • Grochola LF; Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Psychiatry, Amsterdam Neuroscience, the Netherlands.
  • Palles C; Department of Surgery, Cantonal Hospital Winterthur, Switzerland.
  • Protheroe A; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Millar V; Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
  • Ebner DV; Target Discovery Institute, University of Oxford, Nuffield Department of Medicine, Oxford, United Kingdom.
  • Pagadala M; Target Discovery Institute, University of Oxford, Nuffield Department of Medicine, Oxford, United Kingdom.
  • Blagden SP; Department of Medicine, University of California, San Diego, La Jolla, California.
  • Maughan TS; Department of Oncology, University of Oxford, Oxford, United Kingdom.
  • Domingo E; Department of Oncology, University of Oxford, Oxford, United Kingdom.
  • Tomlinson I; Department of Oncology, University of Oxford, Oxford, United Kingdom.
  • Turnbull C; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom.
  • Carter H; Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.
  • Bond GL; Department of Medicine, University of California, San Diego, La Jolla, California. G.Bond.1@bham.ac.uk hkcarter@health.ucsd.edu.
Cancer Res ; 81(7): 1667-1680, 2021 04 01.
Article in En | MEDLINE | ID: mdl-33558336
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Suppressor Protein p53 / Drug Resistance, Neoplasm / Neoplasms Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Animals / Female / Humans / Male Language: En Journal: Cancer Res Year: 2021 Document type: Article Affiliation country: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Suppressor Protein p53 / Drug Resistance, Neoplasm / Neoplasms Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Animals / Female / Humans / Male Language: En Journal: Cancer Res Year: 2021 Document type: Article Affiliation country: Reino Unido